Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Oct 13:15:686.
doi: 10.1186/s12885-015-1683-1.

Do Multidisciplinary Team (MDT) processes influence survival in patients with colorectal cancer? A population-based experience

Affiliations
Meta-Analysis

Do Multidisciplinary Team (MDT) processes influence survival in patients with colorectal cancer? A population-based experience

Alastair Munro et al. BMC Cancer. .

Abstract

Background: MDT (multidisciplinary team) meetings are considered an essential component of care for patients with cancer. However there is remarkably little direct evidence that such meetings improve outcomes. We assessed whether or not MDT (multidisciplinary team) processes influenced survival in a cohort of patients with colorectal cancer.

Methods: Observational study of a population-based cohort of 586 consecutive patients with colorectal cancer diagnosed in Tayside (Scotland) during 2006 and 2007.

Results: Recommendations from MDT meetings were implemented in 411/586 (70.1 %) of patients, the MDT+ group. The remaining175/586 (29.9 %) were either never discussed at an MDT, or recommendations were not implemented, MDT- group. The 5-year cause-specific survival (CSS) rates were 63.1 % (MDT+) and 48.2 % (MDT-), p < 0.0001. In analysis confined to patients who survived >6 weeks after diagnosis, the rates were 63.2 % (MDT+) and 57.7 % (MDT-), p = 0.064. The adjusted hazard rate (HR) for death from colorectal cancer was 0.73 (0.53 to 1.00, p = 0.047) in the MDT+ group compared to the MDT- group, in patients surviving >6 weeks the adjusted HR was 1.00 (0.70 to 1.42, p = 0.987). Any benefit from the MDT process was largely confined to patients with advanced disease: adjusted HR (early) 1.32 (0.69 to 2.49, p = 0.401); adjusted HR(advanced) 0.65 (0.45 to 0.96, p = 0.031).

Conclusions: Adequate MDT processes are associated with improved survival for patients with colorectal cancer. However, some of this effect may be more apparent than real - simply reflecting selection bias. The MDT process predominantly benefits the 40 % of patients who present with advanced disease and conveys little demonstrable advantage to patients with early tumours. These results call into question the current belief that all new patients with colorectal cancer should be discussed at an MDT meeting.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart illustrating the population of patients and outcomes
Fig. 2
Fig. 2
Kaplan-Meier survival curves for cause-specific survival according to MDT group
Fig. 3
Fig. 3
Kaplan-Meier cause-specific survival curves according to extent of disease (for definition see text) and MDT group

References

    1. Calman K, Hine D. A policy framework for commissioning cancer services: a report by the expert advisory group on cancer to the chief medical officers of England and wales. 1995.
    1. Selby P, Gillis C, Haward R. Benefits from specialised cancer care. Lancet. 1996;348(9023):313–8. doi: 10.1016/S0140-6736(96)02482-8. - DOI - PubMed
    1. Department of Health . The NHS cancer plan, A plan for investment, A plan for reform. London: Department of Health; 2000.
    1. Du CZ, Li J, Cai Y, Sun YS, Xue WC, Gu J. Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy. World J Gastroenterol. 2011;17(15):2013–8. doi: 10.3748/wjg.v17.i15.2013. - DOI - PMC - PubMed
    1. Lordan J, Karanjia N, Quiney N, Fawcett W, Worthington T. A 10-year study of outcome following hepatic resection for colorectal liver metastases - The effect of evaluation in a multidisciplinary team setting. Eur J Surg Oncol. 2009;35(3):302–6. doi: 10.1016/j.ejso.2008.01.028. - DOI - PubMed

Publication types